Biotech Values

[ghmm]

NKTR:

The Q&A on the conference call (as has been common lately) focused around 214. The company did not disclose much new information. They did say there have been no reports of Vascular Leak Syndrome (I did a little searching and saw that is a common IL2 side effect http://www.ncbi.nlm.nih.gov/pubmed/9403331 ). They reiterated the plan to start combination studies later this year and to provide some top-line data as a single agent (though they expect some patients to be on drug). One analyst really tried to push to at least see where they were but no luck. Said even with initial dose would expect to see some activity but no mention of what cohort (they are planning 6) or how many patients are enrolled.

In other news... 181 (their pain drug) completed enrollment and top-line data still expected for Q1 '17. Human abuse trial to start Q4 with data in Q2 '17. IND for NKTR-358 (autoimmune diseases) planned for Q1 '17. Phase 3 readouts from Bayer programs Cipro inhale and Amikacin inhale still 2H '16/Q1 '17. Ophthotech’s Fovista Q4 '16 readout.

Transcript: http://seekingalpha.com/article/3995447-nektar-therapeutics-nktr-ceo-howard-robin-q2-2016-results-earnings-call-transcript?part=single